Bromolac 2.5

Indications

Conditions Linked to Hyperprolactinemia: This encompasses dysfunctions associated with hyperprolactinemia, such as amenorrhea, with or without galactorrhea, infertility, or hypogonadism.

Prolactin-Secreting Adenomas: In cases where adenectomy is chosen, a regimen of bromocriptine mesylate therapy may be utilized to diminish tumor mass before surgery.

Acromegaly and Parkinson’s Disease: Bromocriptine mesylate serves as an adjunctive therapy to levodopa for idiopathic or postencephalitic Parkinson’s disease. It also addresses elevated growth hormone levels in acromegaly cases.

Pharmacological Profile

Bromocriptine mesylate acts as a nonhormonal, nonestrogenic agent, primarily inhibiting prolactin secretion in humans. Its dopamine receptor agonist nature targets post-synaptic dopamine receptors, modulating prolactin secretion in the anterior pituitary. Additionally, it has a role in controlling motor function through dopaminergic neurons in the corpus striatum.

Dosage & Administration

General: Bromocriptine mesylate is ideally consumed with food. Patients should undergo frequent evaluation during dose escalation to determine the lowest effective dosage.

Hyperprolactinemic Indications: Initial dosage typically ranges from 0.5 mg to 2.5 mg daily, with adjustments made every 2-7 days until therapeutic response is attained.

Acromegaly: Initial recommended dosage ranges from 0.5 mg to 2.5 mg before retiring, with gradual adjustments every 3-7 days as tolerated.

Parkinson’s Disease: Treatment begins with a low dosage of 0.5 of a 2.5 mg tablet twice daily with meals, with incremental increases every 14-28 days if necessary.

Interactions

Bromocriptine mesylate may interact with dopamine antagonists and certain other agents, affecting its efficacy. Concomitant use with other ergot alkaloids is discouraged.

Contraindications

Bromocriptine mesylate is contraindicated in cases of uncontrolled hypertension, sensitivity to ergot alkaloids, and during pregnancy.

Side Effects

Common side effects include nausea, headache, dizziness, and fatigue, among others. Temporary dosage reduction may alleviate adverse reactions.

Pregnancy & Lactation

Bromocriptine mesylate falls under pregnancy category B and should not be used during lactation.

Precautions & Warnings

Caution is advised when administering bromocriptine mesylate to patients with renal or hepatic disease, or those on medications known to lower blood pressure. Special attention is needed in patients with a history of psychosis or cardiovascular disease.

Use in Special Populations

Data on bromocriptine use in pediatric patients under 8 years old are unavailable.

Therapeutic Class

Antiparkinson drugs, Motility stimulants/Dopamine antagonist

Storage Conditions

Store below 30°C, away from light and moisture. Keep out of reach of children.